# Progress of long-chain noncoding small nucleolar RNA host genes in thyroid cancer

## TL;DR

This paper reviews how certain long non-coding RNAs, called SNHGs, are involved in thyroid cancer progression and could be used as biomarkers or treatment targets.

## Contribution

The paper systematically summarizes the roles of specific SNHGs in thyroid cancer and highlights their potential as biomarkers and therapeutic targets.

## Key findings

- SNHG7 promotes thyroid cancer cell growth and resistance to treatment via the PI3K/Akt pathway.
- SNHG15 and SNHG12 contribute to cancer progression through Hippo-YAP1 and Wnt/β-catenin signaling, respectively.
- SNHG3 and SNHG5 show tumor-suppressive effects in some studies, suggesting a dual role for SNHGs.

## Abstract

Small nucleolar RNA host genes (SNHGs) are a class of long non-coding RNAs that are widely aberrantly expressed in thyroid cancer and regulate tumor progression through the “SNHG–miRNA–signaling pathway” network. SNHG7 promotes cell proliferation and metastasis via the PI3K/Akt pathway and correlates with radioactive iodine resistance; SNHG15 accelerates epithelial-mesenchymal transition via the Hippo-YAP1 pathway; SNHG12 drives malignant phenotypes by interacting with Wnt/β-catenin signaling; SNHG14 enhances tumor invasion through multiple miRNA axes. In contrast, SNHG3 and SNHG5 exhibit tumor-suppressive effects in some studies. Overall, SNHGs may serve as molecular biomarkers and hold potential therapeutic target value. However, existing evidence is largely based on in vitro and small-sample studies, requiring further validation in clinical cohorts and functional models.